SRR934754
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 80.05913272010513
- age_years
- 32
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.459
- NOTCH_SIGNALING+0.427
- INTERFERON_ALPHA_RESPONSE+0.397
- TGF_BETA_SIGNALING+0.373
- ANDROGEN_RESPONSE+0.370
- UV_RESPONSE_DN+0.338
- INTERFERON_GAMMA_RESPONSE+0.326
- OXIDATIVE_PHOSPHORYLATION+0.304
- MTORC1_SIGNALING+0.284
- ADIPOGENESIS+0.281
Top 10 suppressed
- KRAS_SIGNALING_DN-0.359
- SPERMATOGENESIS-0.188
- MYOGENESIS-0.177
- APICAL_JUNCTION-0.176
- APICAL_SURFACE-0.167
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.160
- PANCREAS_BETA_CELLS-0.156
- COAGULATION-0.137
- ANGIOGENESIS-0.112
- HYPOXIA-0.057
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934819 | — | — | 0.919 |
| 2 | SRR934795 | — | — | 0.904 |
| 3 | SRR934764 | — | — | 0.899 |
| 4 | SRR934756 | — | — | 0.896 |
| 5 | C969CDC5-D2DC-4F7B-B84B-C53CEF26B2CF | — | — | 0.891 |
| 6 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.879 |
| 7 | 0CEC1ADC-1E8E-4CAC-8DFD-E1A760064E58 | — | — | 0.874 |
| 8 | 4099642A-F8D6-428C-AA12-1E76C27BB368 | — | — | 0.867 |
| 9 | 33060001-05C9-4751-AA58-F194207ACC08 | — | — | 0.867 |
| 10 | SRR934762 | — | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.459 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.427 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.397 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.373 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.338 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.326 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.304 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.284 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.281 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.274 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.273 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.241 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.233 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.206 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.205 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.198 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.192 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.187 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.187 | Temsirolimus | — uncovered |